ERBB2 and infection: To assess the potential of the T-DM1 combination with VSVΔ51 in HER2-overexpressing cancer cells, we pretreated JIMT1 cells with increasing concentrations of T-DM1 for 4 h followed by infection with VSVΔ51 at a low MOI.